izencitinib: Clinical Trials

7 trials of izencitinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated. 5 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 5
Phase 22Terminated 2

Follow izencitinib: new trials by email Literature Review of izencitinib trials Research Report on izencitinib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects
TD-1473 [Tablet A], TD-1473 [Tablet B] - Intestinal Disorder, Bowel Diseases, Inflammatory
Phase 1CompletedTheravance Biopharma582020-10-162021-04-09
Rifaximin in Patients With Diabetic Gastroparesis
Rifaximin, Placebo - Crohn Disease, Diabetic Gastroparesis
Phase 2TerminatedMayo Clinic52019-06-142026-06-22
Efficacy and Safety of TD-1473 in Crohn's Disease
Placebo, TD-1473 - Crohn's Disease
Phase 2TerminatedTheravance Biopharma1672018-11-192023-03-13
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
TD-1473, Itraconazole - Inflammatory Bowel Disease
Phase 1CompletedTheravance Biopharma362018-06-132021-01-14
TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule - Intestinal Disorders, Bowel Diseases, Inflammatory
Phase 1CompletedTheravance Biopharma202018-01-312021-01-14
TD-1473 for Active Ulcerative Colitis (UC)
TD-1473, Placebo - Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Phase 1CompletedTheravance Biopharma402016-10-032021-09-30
SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects
TD-1473 for SAD, Placebo for SAD, TD-1473 for MAD - Healthy
Phase 1CompletedTheravance Biopharma722015-12-012021-01-19

Conditions studied

Inflammatory Bowel Diseases (4)  ·  Crohn Disease (2)  ·  Intestinal Diseases (2)  ·  Colitis, Ulcerative (1)  ·  Irritable Bowel Syndrome (1)

Sponsors

Theravance Biopharma (6)  ·  Mayo Clinic (1)

Countries

United States (7)  ·  Georgia (2)  ·  Romania (2)  ·  Australia (1)  ·  Austria (1)  ·  Bulgaria (1)  ·  Croatia (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Hungary (1)  ·  Israel (1)  ·  Moldova (1)  ·  New Zealand (1)  ·  Poland (1)

Top investigators

Brian E Lacy (1)

Results publications

PMID 32161949

NIH funding

2016 (1), 2018 (1)